

CURRICULUM VITAE

NAME: James H. Revkin

HOME ADDRESS:
12 Highland Avenue
Branford, CT 06405-4715
U.S.A

TELEPHONE: mobile: +1 203 619 2247
e-mail: james.revkin@gmail.com

WORK ADDRESS 1:

Pfizer Inc.
Global Innovative Pharma Business
Clinical Sciences
MS 8260-2277
445 Eastern Point Road
Groton, CT 06340
U.S.A.
Tel: +1 860 441 4214
Email: james.h.revkin@pfizer.com

WORK ADDRESS 2:

Yale University School of Medicine
Section of Cardiovascular Medicine
333 Cedar Street
New Haven, CT 06510
Tel: +1 (203) 785-7191
e-mail: james.revkin@yale.edu
http://cardio.med.yale.edu/people/james_revkin.profile

BIRTHPLACE: Providence, RI

CITIZENSHIP: United States

EDUCATION: Williams College, Williamstown, MA
B.A. (Philosophy), *cum laude*, 1976

Brown University, Providence, RI
M.D., 1981

PRESENT POSITIONS:

**Senior Director
Global Clinical Lead, Bococizumab (PF-04950615)
Cardiovascular Outcome Studies, SPIRE 1, SPIRE 2**

**Pfizer Inc.
Global Innovative Pharma, Clinical Sciences
Groton, CT**

**Associate Clinical Professor of Medicine
Yale University School of Medicine
Section of Cardiovascular Disease
New Haven, Connecticut, USA**

RESEARCH AND PROFESSIONAL EXPERIENCE:

- 1974-75 Student, Université de Paris III, Paris, France. Awarded Certificate Pratique de Langue Française and Diplôme d'Etudes Françaises.
- 1976 Independent student research project co-sponsored by the Department of Pathology, Brown University and Rhode Island Hospital and Department of Biology, Williams College. Study of histologic changes seen in lymphoid tissue B and T cell regions after treatment with immunosuppressive agents.
- 1979 Medical Student Research Fellowship, Department of Physiological Biochemistry, Brown University. Isolation and characterization of an adenosine binding protein in rat adipocyte membranes.
- 1981-84 Resident in the Department of Medicine and Visiting Clinical Fellow at the College of Physicians and Surgeons of Columbia University, Columbia-Presbyterian Medical Center, New York, NY.
- 1982 Research elective, Department of Cardiology, Columbia-Presbyterian Medical Center. Studied techniques of cellular electrophysiology including micro-electrode and voltage clamping of purkinje fibers to characterize various anti-arrhythmic agents and participated in closed chest canine studies of myocardial infarction to study the effects of beta-blockers on inducible ventricular arrhythmias and the ventricular fibrillation threshold.
- 1984-87 Postdoctoral Fellow, Section of Cardiology, Department of Medicine,

- Yale University School of Medicine, New Haven, CT.
- 1986 Senior Fellow and Attending Physician, Cardiac Catheterization Laboratory, West Haven VA Hospital, West Haven, CT.
- 1984-87 Clinic Physician, East Haven Medical Clinic, East Haven, CT.
- 1984-87 House Physician and House Physician Coordinator (1986-87), Milford Hospital, Milford, CT
- 1985-87 Emergency Room and House Physician, St. Joseph Hospital, Stamford, CT.
- 1987-88 Locum Tenens Physician, Department of Medicine, Group Health Cooperative of Puget Sound, Seattle, WA.
- 1987-88 Postdoctoral Fellow, Cardiovascular Research Trainee, Center for Bioengineering, University of Washington, Seattle, WA.
- 1988-90 Assistant Professor of Medicine, Director, Heart Failure/Transplant Cardiology Program, Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA.
- 1990-1993 Assistant Professor of Medicine, Director, Yale University Heart Failure Center/Transplant Cardiology Program, Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT.
- 1990-1993 Medical Student Clinical Correlations Tutor/Advisor Classes of 1994 and 1996, Yale University School of Medicine, New Haven, CT, (Robert H. Gifford, M.D., Coordinator).
- 1993-1999 Yale University School of Medicine, Primary Care Program, Residency Selection Committee.
- 1994-1995 Assistant Clinical Professor of Medicine, Yale Heart Failure Center Transplant Cardiology Program, Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT.
- 1993-1999 Director of Section of Cardiovascular Medicine Waterbury Hospital Health Center, Waterbury, CT.
- 1995-present Associate Clinical Professor of Medicine, Yale Heart Failure Center Transplant Cardiology Program, Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT.

- 1999-2008 Associate Director (1999-2003)
Sr. Associate Director (2003-2004)
Director (2004-2007)
Senior Director (2007-2008)
Clinical Leader, CETP Inhibitor Programs (2006-2008)
Clinical Research and Development
Pfizer Global Research and Development
New London, CT
- 2008-2012 Executive Director, USA Therapeutic Area Director
Cardiovascular and Metabolic Diseases, Clinical Operations
Boehringer Ingelheim Pharmaceuticals Inc. USA
Ridgefield, CT
- 2012-Present Senior Director, Global Clinical Lead
Bococizumab CV Outcomes Program
Global Innovative Pharma
Clinical Sciences
Pfizer Inc.
Groton, CT

MEDICAL LICENSURE:

State of Connecticut, 1984 (#025158)
State of New York, 1982 (#150490) (inactive)
State of Washington, 1986 (#252-09-0024297)(inactive)

ADDITIONAL LICENSURE AND CERTIFICATION:

Certified Instructor, Basic Cardiac Life Support, American Heart Association and
Regional Emergency Medical Services Corp. of New York, 1983.

Advanced Cardiac Life Support (ACLS), American Heart Association, 1979,
recertified 1984, 1997, 1999.

Drug Enforcement Agency License #AR2501016.

Diplomate, National Board of Medical Examiners, July 1, 1982,
(Certificate #242789).

Diplomate, American Board of Internal Medicine, September 12, 1984,
(Certificate #095938).

Diplomate, Subspecialty of Cardiovascular Disease, American Board of Internal
Medicine, November 10, 1987 (Certificate #095938).

Diplomate, Subspecialty of Critical Care Medicine, American Board of Internal Medicine, November 19, 1997, effective through 2007. (Certificate #095938).

Basic Cardiac Life Support C, American Heart Association, Recertification 2014.

HONORS:

- 1976 Graduated *cum laude* in Philosophy, Williams College
- 1976 Elected to *Phi Beta Kappa*, Williams College
- 1981 Elected to *Sigma Xi*, Brown University

GRANTS:

- 1986-87 Awarded American Heart Association, Connecticut Affiliate, Research Fellowship at Yale University School of Medicine, Sections of Endocrinology-Metabolism and Cardiology. The study of the metabolic characteristics of reperfused myocardium.
- 1987-89 Simulation Resource in Mass Transport and Exchange, Center for Bioengineering, University of Washington, collaborating investigator, (P.I., James B. Bassingthwaite, M.D., Ph.D.).
- 1988-90 Awarded American Heart Association, Washington Affiliate, Grant-in-Aid: Myocardial amino acid transport and tracer development.
- 1988-90 Principal Investigator at the University of Washington for a series of investigations pertaining to the use of Enoximone in the treatment of congestive heart failure, funded by the Merrell Dow Research Institute, Cincinnati, OH.
- 1990 Co-Investigator at University of Washington and Yale University School of Medicine, A Randomized Phase III, Placebo Controlled Survival Study of Oral Milrinone in Patients with Severe Congestive Heart Failure, Sterling Research Group, Malvern, PA.
- 1992-1994 Principal Investigator at Yale University School of Medicine, The Effects of Amlodipine in Subjects Being Treated for Chronic Heart Failure, Pfizer Inc., Central Research, Groton CT.
- 1992-1994 Co-Investigator at Yale University School of Medicine, Multi-center Study of the Effects of Chronic Intravenous Epoprostenol/Prostacyclin Therapy on Survival in Subjects with Refractory Severe Congestive Heart Failure, Burroughs-Wellcome Co., Research Triangle Park, Durham, NC.

- 1993-1997 Co-Investigator at Yale University School of Medicine, Carvedilol in Heart Failure Trial: A Six-month Double-Blind Multicenter Comparison of Oral Carvedilol B.I.D. with Placebo in Patients with Congestive Heart Failure, NYHA Class II-IV, SmithKline Beecham Pharmaceuticals, US Division, King of Prussia, PA.
- 1993-1997 Principal Investigator at Yale University School of Medicine, A randomized multiple dose study of the chronic administration of Vesnarinone (OPC-8212) in heart failure (OPC Protocol No. 22-92-206). Otsuka America Pharmaceutical Inc., Maryland Office of Clinical Research, Rockville, MD.
- 1993-1995 Principal Investigator at Waterbury Hospital Health Center, A phase 3 randomized, double blind, dose response, positive control comparative evaluation of the efficacy and safety of OPC-18790 in the treatment of patients with decompensated heart failure, and its extension study (Protocols 103-93-201 and -202). Otsuka America Pharmaceutical Inc., Maryland Office of Clinical Research, Rockville, MD.
- 1994-1997 Principal Investigator at Yale University School of Medicine, A randomized, double blind, placebo controlled, multiple dose study of the chronic administration of Vesnarinone (OPC-8212) in heart failure (OPC Protocol No. 22-94-201). Otsuka America Pharmaceutical Inc., Maryland Office of Clinical Research, Rockville, MD.
- 1996-1997 Principal Investigator at Waterbury Hospital Health Center, as a study site for PURSUIT (Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy) which is an evaluation of Integrelin (IND-35,465)--in a phase 3, randomized, double blind evaluation of the efficacy and safety of two dosing regimens of Integrelin versus placebo for reducing mortality and myocardial (re)infarction in subjects with unstable angina or non-Q wave myocardial infarction.
- 1997-1998 Principal Investigator at Waterbury Hospital Health Center, as a study site for Symphony: Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post Acute Coronary Syndromes). The Phase 3 study will compare the efficacy, safety, and tolerability of sibrafiban, an oral platelet glycoprotein IIb/IIIa antagonist, in low dose regimens to that of aspirin in patients following an acute coronary syndrome (myocardial infarction or unstable angina).
- 1997-1999 National Registry of Myocardial Infarction (NRMI-3), Physician Investigator, Waterbury Hospital.
- 1999-2000 Pfizer Inc., Lead Clinical for PATH Phase 4, Studies I and II to assess safety and efficacy of amlodipine in children with hypertension in support of pediatric exclusivity.

2000-2008 Pfizer Inc., Lead Clinician overseeing conduct of four Phase 2 and six global Phase 3 clinical trials assessing the efficacy and safety of torcetrapib and torcetrapib/atorvastatin (IVUS study in subjects with coronary artery disease, carotid ultrasound studies [2] in subjects with mixed dyslipidemia and heterozygous familial hypercholesterolemia, and lipids trials in subjects with Fredrickson Type III and IV dyslipidemia, and a comparator study with simvastatin/ezetimibe.

Designed Phase 3 vascular imaging program for the development torcetrapib/atorvastatin (one coronary IVUS study with Dr. Steven Nissen, Cleveland Clinic and Jean-Claude Tardif, Montreal Heart Institute and two carotid ultrasound (intima-media thickness) studies with Dr. Ward Riley, Wake Forest University and Dr. Michiel Bots, Utrecht, Netherlands. Interacted with FDA Metabolism Division (D Orloff/M Parks) and EMA/CHMP scientific advice meeting, as Pfizer subject matter expert for vascular imaging

Appointed Global Clinical Lead for torcetrapib-atorvastatin and CETP inhibitor backup program, Jan 2007. Charged with overseeing wrap-up of Phase 3 Program, Summary Documents and Follow-Up Study in subjects exposed to torcetrapib in 2006.

Committee Chairman, Cardiovascular Safety Subcommittee, Cardiac Structure, Function, and Metabolism 2007

Appointed Global Clinical Lead, Apixaban DVT prevention program, BMS-Pfizer Alliance, Oct 2007

2008-2012 Boehringer-Ingelheim
Therapeutic Area Director, Cardiovascular and Metabolic Diseases: operational management support for the following therapeutic targets-

Thrombosis: Dabigatran projects (SPAF, VTE treatment and primary and secondary prevention), supported submissions for indication of stroke prevention in patients with atrial fibrillation, and was a respondent at the FDA Cardio-Renal Advisory Committee meeting, [20 Sep 2010](#). Team Member Medicine (TMM) dabigatran for three projects; primary prevention of VTE after orthopedic surgery, acute treatment of VTE, and extended treatment of VTE or secondary prevention of VTE recurrence.

Diabetes: DPP-IV (linagliptin) and SGLT-2 inhibitor projects (US investigator oversight, provided expertise on design of CV outcomes studies, provided advice on strategy for minority population recruitment)

Atherosclerosis: targets in research including mechanisms of vascular inflammation and dyslipidemia (CETP inhibition), biologics and small molecules.

Member of transition teams for the CETP inhibitor BI-415756 and the FLAP inhibitor BI-665915

Licensing: Have participated on due diligence evaluations of CETP inhibitors and Apo A-I Milano mimetic therapeutics on behalf of Boehringer Ingelheim and Pfizer.

2012-Present Pfizer Inc.

The Global Clinical Lead overseeing the design and execution of the bococizumab (PF-04950615) PCSK9 inhibitor cardiovascular outcomes studies, SPIRE-1 and SPIRE-2. Informed design of lipid lowering studies based on the design of the CV outcomes studies.

Subject matter expert on cardiovascular imaging and lipid metabolism

Spearheaded constitution of academic steering committee

Spearheaded constitution and of independent data monitoring committee

Spearheaded constitution and oversight of academic adjudication committee

Participation in development of safety monitoring plans and development of automated safety narratives

Member, Cardiovascular Safety Committee

STATE, NATIONAL, INTERNATIONAL COMMITTEES:

United Network for Organ Sharing (UNOS), Region I (New England) representative for the Cardiothoracic Transplantation Committee, (1991-1993).

American Heart Association, Abstract Reviewer for 1992 Scientific Sessions, Section on Heart Transplantation.

Acute Myocardial Infarction Study Group, Connecticut Peer Review Organization, Inc., Middletown, CT. (1993- 1999).

Connecticut Healthcare Research and Educational Foundation, Inc., member, "Toward excellence in Care" Clinical Panel on Cardiology, Wallingford, CT. (1997-1999)

American College of Physicians, Connecticut Chapter, Abstract reviewer for Spring 1997 and 1998 sessions.

American Heart Association, Connecticut Affiliate, CME committee member, 1997 to 1999.

American Heart Association, Heritage Affiliate, Task Force on Professional Education, member, 1998-99.

Connecticut Healthcare Research and Educational Foundation, Inc., member, "Toward Excellence in Care" Committee on Research and Data, Wallingford, CT, June 16, 1999 to October 4, 1999.

Foundation of the National Institutes of Health, Biomarker Consortium, Industry Representative, Boehringer Ingelheim Pharmaceuticals Inc., Bethesda, MD, June 2008 to 2012.

CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy, 2011 to present.

RESEARCH INTERESTS:

Myocardial metabolism, including substrate utilization and protein turnover in health and disease, as studied with metabolic tracer techniques. Clinical studies assessing the efficacy and safety of medications used in the treatment of dyslipidemia, heart failure, hypertension, and coronary artery disease. Subject matter specialist in the use of vascular imaging to assess slowing the progression of atherosclerosis.

CLINICAL ACTIVITIES:

On clinical staff of Yale-New Haven Hospital, where Dr. Revkin sees patients, as a faculty volunteer, in the Cardiovascular Fellows' Clinic. He provides teaching to Yale Fellows and Medical Students (lectures on Lipids and ECG reading). Dr. Revkin also supervises Yale Medical Students who provide blood pressure and diabetes screening, as a volunteer, in the Yale Sponsored New Haven Health Project, New Haven, CT, periodically on Saturday mornings.

SOCIETIES:

- 1976-present Phi Beta Kappa
- 1981-present Sigma Xi
- 1985-present American College of Physicians (Member #082235), Elected to Fellowship 1990 (FACP).
- 1985-present American Heart Association, Member
- 1985-present American College of Cardiology (Member #601885), Elected to Fellowship 1989 (FACC).
- 1988-2001 International Society for Heart and Lung Transplantation, Member
- 1996-present American College of Chest Physicians, Elected to Fellowship 1996 (FCCP)
- 1998-2000 American Society of Nuclear Cardiology, Member

Languages:

English: Native

James H. Revkin, M.D.

French: High level of fluency

Spanish: Basic, conversant in medical Spanish, for patient care.

German: Basic

INVITED PRESENTATIONS (selected):

European Society of Cardiology, Cardiovascular Round Table, CRT TF1 Imaging Biomarkers Meeting. Presentation Title: *The role of vascular imaging in 2006, clinical relevance versus surrogacy, the weight of the evidence.* Amsterdam, Netherlands, 2 May 2006

Yale University School of Medicine: Pathophysiology Cardiovascular Core Lecture, Dyslipidemias: Cholesterol, the good, the bad, and the ugly. New Haven, CT, USA, 8 Sept. 2006.

EMA/EFPIA Workshop on Biomarkers. Presentation Title: *Torcetrapib/atorvastatin: A state-of-the-art case study in imaging biomarker utilization for registration.* J. Revkin author (slides presented by William Vennart). London, UK, 15 Dec 2006

DIA Annual Meeting, Surrogate Endpoints in Cardiovascular Drug Development. Presentation Title: *Surrogate Markers in Cardiovascular Disease: An Industry Perspective.* Atlanta, Georgia, USA, 18 June 2007.

Yale Affiliated Hospitals Teaching Program: *Lipoproteins and Atherosclerosis.* Greenwich Hospital Medical Grand Rounds, Greenwich, CT, USA, 20 July 2007.

Invited lecture, in French, *Torcetrapib, Les Résultats ILLUMINÉ,* Pavillon Benjamin Delessert, Hôpital de la Pitié, INSERM Unité 321, Paris, France, 5 Décembre 2007

Tenth Annual Cardiovascular Clinical Trialists Workshop 2007. *Vascular Imaging and Clinical Endpoint Studies: The challenges for the development of new cardiovascular therapies.* Sponsored by CIC, INSERM, ESC, NHLBI, Paris, France, 7 December 2007

Yale Affiliated Hospitals Teaching Program: *Lipoproteins and Atherosclerosis.* Saint Mary's Hospital, Medical Housestaff Lecture, Waterbury, CT, USA, 9 Jan 2008.

Yale Affiliated Hospitals Teaching Program: *Cardiometabolic Risk: Lipoprotein Management,* Bridgeport Hospital/Yale-New Haven Health, Medical Grand Rounds, Bridgeport, CT, USA, 13 Aug 2009.

ESC Working Group on Cardiovascular Pharmacology and Drug Therapy, Risk Stratification Guided Cardiovascular Preventive Drug Therapy, invited faculty speaker, with presentation title *Emerging biomarkers and bioimaging: any additional value?* Paris, France, 18-19 Sep 2009.

6th Global Cardiovascular Clinical Trialists Forum, CVCT Expert Workshops, sponsored by Centre d'Investigation Clinique-INSERM, Nancy, France (1) *Antithrombotic Acute Coronary Syndrome Trials, Methodological and Interpretation Issues and Data Safety and Monitoring Committees in CV Trials,* Invited Industry Faculty member, Paris, France, 5 Dec 2009.

International Conference on Early Disease Detection and Prevention 2010, Session: The Impact of Early Detection and Prevention on Health Policy, Invited speaker: *Early Disease Prevention and Detection, the Industry Perspective*. Munich, Germany, 28 Feb 2010.

Invited lecture: Recent Advances in Lipids, Sultan Qaboos University, College of Medicine and Health Sciences, Muscat, Sultanate of Oman, 3 Mar 2010

Invited lecture: Two Cardiovascular Endpoint studies, ONTARGET and RE-LY, Oman Heart Association, Muscat, Sultanate of Oman, 6 Mar 2010

Yale Affiliated Hospitals Teaching Program: *Cardiac Transplantation, an update*. Hospital of Saint Raphael/Cardiology Fellow's Conference, New Haven, CT, USA, 13 Oct 2010.

Yale Affiliated Hospitals Teaching Program: *Cardiometabolic Risk: Lipoprotein Management*, Saint Mary's Hospital/Housestaff lecture, Waterbury, CT, USA, 27 Apr 2011.

Yale Affiliated Hospitals Teaching Program: *Cardiometabolic Risk: Lipoprotein Management*, Norwalk Hospital//Cardiology Grand Rounds, Norwalk, CT, USA, 25 May 2011.

Yale Affiliated Hospitals Teaching Program: *HDL as a Therapeutic Target*. Greenwich Hospital Subspecialty/Cardiology Rounds, Greenwich, CT, USA, 10 Aug 2011.

Yale Affiliated Hospitals Teaching Program: *Cardiometabolic Risk: Lipoprotein Management*, Norwalk Hospital//Cardiology Grand Rounds, Norwalk, CT, USA, 12 Jan 2012

Yale University School of Medicine: Section of Cardiovascular Medicine, Basic Science Lecture: *Trials and Tribulations, sometimes Jubilation, An Overview of Pharmaceutical Drug development*, New Haven, CT, USA, 25 Jan 2012.

Yale Affiliated Hospitals Teaching Program: *PCSK9 inhibition and Lipid Metabolism*, Norwalk Hospital//Cardiology Grand Rounds, Norwalk, CT, USA, 13 Jan 2016

Yale Affiliated Hospitals Teaching Program: *PCSK9 inhibition and Lipid Metabolism*, Bridgeport Hospital//Medical Grand Rounds, Norwalk, CT, USA, 18 Feb 2016

ABSTRACTS:

Barrett E, Revkin J, Young L, Zaret B and Gelfand R. An isotopic method for *in vivo* measurement of muscle protein synthesis and degradation. Clin Res 34:540A, 1986. (Presented at AAP/ASCI/AFCR national meeting, 1986)

Revkin J, Young L, Zaret B, Gelfand R, Jacob R and Barrett E. A novel isotope dilution technique to measure protein turnover in heart muscle. Clin Res 34:338A, 1986. (Presented at AAP/ASCI/AFCR national meeting, 1986)

Revkin J, Young L, Zaret BL, Gelfand R, Jacob R and Barrett EJ. Labeled amino acid tracers and the *in vivo* assessment of myocardial protein synthesis. Clin Res 35:319A, 1987. (Presented at AAP/ASCI/AFCR national meeting, 1987)

Young LH, Revkin J, Zaret B and Barrett EJ. Insulin stimulates myocardial lactate extraction in the conscious dog: Implications for metabolic assessment of myocardial ischemia. Clin Res 35:337A, 1987. (Presented at AAP/ASCI/AFCR national meeting, 1987)

Revkin J, Barrett E, Young L, Gelfand R, Zaret BL and Stirewalt W. Amino acyl-tRNA validation of the *in vivo* measurement of myocardial protein turnover using an amino acid tracer: [3-H]-phenylalanine. J Am Coll Cardiol 11:142A, 1988.

Young LH, Bowman LK, Revkin JH, Jaffe CC, Barrett EJ, Cabin HS and Cleman M. Cardiac metabolism during coronary angioplasty with fluosol protection: Discordance between LV systolic function and lactate metabolism. J Am Coll Cardiol 11:149A, 1988.

Schwartz LM, Bukowski TR, Revkin JH and Bassingthwaighte JB. Species differences in capillary transport of inosine and adenosine in rabbit and guinea pig hearts. FASEB J 2:A1524, 1988.

Revkin J, Bukowski TR, Schwartz LM and Bassingthwaighte JB. Amino acid tracer transport in the heart. Circ 78:0227A, 1988.

Young LH, McNulty PH, Revkin JH, Gelfand RA, Deckelbaum LI and Zaret BL. Myocardial protein metabolism in man: Use of a new isotopic method. Clin Res 37:307A, 1989.

Flygenring B and Revkin J. Enoximone, a phosphodiesterase inhibitor for treatment of end-stage heart disease. XII Scandinavian Congress of Cardiology, 1989.

Domin W, O'Brien K, Lee C, Lipkin E and Revkin J. Postpartum myocarditis and thyroiditis. American College of Physicians, Washington State Chapter Scientific Meeting. Abstracts. P.9. 2 December 1989.

Revkin JH, Flygenring BP, Fishbein DP and Allen MD. The treatment of pulmonary hypertension in candidates for heart transplant surgery with oral enoximone. Clin Res 38:335A, 1990.

Revkin JH, Flygenring BP, Fishbein DP and Allen MD. The use of oral enoximone in candidates for heart transplantation with severe biventricular failure and pulmonary hypertension. *J Heart Transplant* 10:179, 1991. (Presented at scientific sessions, International Society for Heart and Lung Transplantation, Paris, France, April 1991)

Bassingthwaighte JB, Kroll K, Schwartz LM, Bukowski TR, and Revkin JH. Endothelial purine metabolism: A role in regulating vasomotion? *J Mol Cell Cardiol* 23 (Supplement-III) S 13, 1991.

Jain D, Lee FA, Revkin J, Wackers FJTh, Burg MM, and Zaret BL. Reduced exercise capacity in patients following cardiac transplantation: excellent ventricular function, a primary startling effect but inadequate heart rate response during exercise. *J Nuc Med* 33:939, 1992.

Davidson M, McKenney J, Revkin JH, and Shear CL. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor torcetrapib, when administered with and without atorvastatin to subjects with a low level of high-density lipoprotein cholesterol. *J Am Coll Cardiol* 2005;45 (3) Supp. : 802-3-394A

Kastelein JJP, Bots ML, Riley WA, Evans GW, Meijer R, Revkin JH, Raszewska J, Shear CL and Thuren T. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia . *Atherosclerosis* 2005; 6 (1, Supp): 51-52.

Bots ML, Riley WA, Evans GW, Kastelein JJP, Revkin JH, Thuren T, Shear CL and Nguyen TT Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemia *Atherosclerosis* 2005; 6 (1, Supp): 48

Nissen SE, Tardif J-C, Crowe T, Thuren T, Shear CL, and Revkin JH Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease. *Atherosclerosis* 2005; 6 (1, Supp): 116

Revkin J, Durham K, Shear C, Nguyen T. Inhibition of CETP by torcetrapib raises HDL-C and lowers LDL-C independent of gender or baseline HDL-C levels. *Atherosclerosis* 2006; 7 (3, Supp): 550

Revkin J, Shear C. Enhanced LDL-C lowering effect of torcetrapib when administered with atorvastatin to subjects with high baseline triglyceride levels *Atherosclerosis* 2006; 7 (3, Supp): 550

Bamberger M, Moya M, Durham K, Shear C, Nguyen T, Revkin J, Rothblat G. The capacity of HDL to stimulate cholesterol efflux is maintained in subjects with and without low HDL-C treated with torcetrapib. *Atherosclerosis* 2006; 7 (3, Supp): 550

Revkin JH, Ose L, Marais A, Pretorius M, Viljoen J, Burgess L, Lan S, Thuren T, Shear CL. Efficacy and safety of combination torcetrapib/atorvastatin versus atorvastatin alone in patients with heterozygous familial hypercholesterolemia. *Circulation* 2006;114 (Supp II):II-318 (1636).

PUBLICATIONS:

Revkin J. Of doctors and Dalai Lamas. *RI Med J* 64:254-55, 1981.

[Barrett EJ, Revkin JH, Young LH, Zaret BL, Jacob R and Gelfand RA. An isotopic method for measurement of muscle protein synthesis and degradation *in vivo*. *Biochem J* 245:223-228, 1987.](#)

[Young LH, Jaffe CC, Revkin JH, McNulty PH and Cleman M: Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. *Am J Cardiol* 65:986-990, 1990.](#)

[Revkin JH, Young LH, Stirewalt WS, Dahl DM, Gelfand RA, Zaret BL and Barrett EJ. *In vivo* measurement of myocardial protein turnover using an indicator dilution technique. *Circ Res* 67\(4\):902-912, 1990.](#)

[Allen MD, Denny CF, Kruse AP, Revkin JH, Fishbein DP, and Ashley RL. Limited cytomegalovirus-specific immunoglobulin M and immunoglobulin G profiles in cardiac transplant patients. *J Heart Lung Transplant* 10:664-73, 1991.](#)

Revkin JH. Cardiogenic Shock: An Overview, *in* Infertility and Reproductive Medicine Clinics of North America (Karlan BY and Surrey ES, eds.) W. B. Saunders Company, Philadelphia. 3: 881-894, 1992.

[Bukowski TR, Moffett TC, Revkin JH, Ploger JD, and Bassingthwaighe JB. Triple-Label Beta Liquid Scintillation Counting. *Analytical Biochemistry* 204:171-180, 1992.](#)

[Young LH, Stirewalt W, McNulty PH, Revkin JH, and Barrett EJ. Effect of insulin on rat heart and skeletal muscle phenylalanyl-tRNA labeling and protein synthesis *in vivo*. *Am J Physiol* 267:E337-E342, 1994.](#)

[Begos DG, Franco KL, Baldwin JC, Lee FA, Revkin JH, and Modlin IM. Optimal timing of cholecystectomy in cardiac transplant patients. *World J Surg* 19:661-667, 1995.](#)

Revkin JH. Cardiology internet resources. *Conn Cardiologist* 3:3, 1996.

Revkin JH and DM Bravata. Cardiogenic pulmonary edema. *J Resp Dis* 17:444-460, 1996.

[Meehan TP, MJ Radford, LV Vaccarino, LD Gottlieb, B McGovern-Hughes, MV Herman, JH Revkin, ML Thierrien, MK Petrillo, HM Krumholz. A collaborative project in Connecticut to improve the care of patients with acute myocardial infarction. *Jt Comm J Qual Improv* 22:751-761, 1996.](#)

[Meehan TP; Radford MJ; Vaccarino LV; Gottlieb LD; McGovern-Hughes B; Herman MV; Revkin JH; Therrien ML; Petrillo MK; Krumholz HM. A collaborative project in Connecticut to improve the care of patients with acute myocardial infarction. Conn Med Mar;61\(3\):147-55, 1997.](#)

[Schwartz LM, Bukowski TR, Revkin JH, Bassingthwaite JB. Cardiac endothelial transport and metabolism of adenosine and inosine. Am J Physiol 1999 Sep;277\(3 Pt 2\):H1241-H1251.](#)

[Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774-1781.](#)

[McKenney JM, Davidson M, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels, on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782-1790.](#)

[Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Reviews. 2007;59:40-53.](#)

[Kastelein JJP, van Leuven S, Evans GW, Riley WA, Revkin JH, Shear CL, and Bots ML, on behalf of the RADIANCE 1 and 2 study investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin 2007; 23: 885–894.](#)

[Nissen SE, Tardif J-C, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzylo W, Bachinsky WB, Lasala GP, Tuzcu EM, for the Illustrate Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.](#)

[Kastelein JJP, van Leuven S, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, and Bots ML, for the RADIANCE 1 investigators. Effect of torcetrapib on progression of carotid atherosclerosis in heterozygous familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.](#)

[Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Grobbee DE, Vicari RM, Kastelein JJ. Torcetrapib and progression of carotid intima-media thickness in mixed dyslipidemia. The RADIANCE II study. The Lancet. 2007;370:153-160.](#)

[Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J-C, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, and Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N. Engl J Med. 2007;357:2109-2122.](#)

[Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Surrogate endpoints in randomized cardiovascular clinical trials. Fundam Clin Pharmacol. 2011 Aug; 25\(4\):411-413.](#)

[Bots ML, Taylor AJ, Kastelein JJ, Peters SA, den Ruijter HM, Tegeler CH, Baldassarre D, Stein JH, O'Leary DH, Revkin JH, Grobbee DE. Rate of change in carotid intima-media thickness and vascular events: meta-analyses cannot solve all the issues. A point of view. J Hypertens. 2012;30\(9\):1690-1696.](#)

[Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Eur J Heart Fail. 2016 May;18\(5\):482-489.](#)

[Ridker PM, Amarencu P, Bruinell R, Glynn RJ, Jukema JW, Kastelein JJP, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, and Yuis C. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events \(SPIRE\) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. Am Heart J 2016;178:135-144.](#)

[Ridker PM, Tardif JC, Amarencu P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 Apr 20;376\(16\):1517-1526.](#)

[Ridker PM, Revkin J, Amarencu P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 2017 Apr 20;376\(16\):1527-1539.](#)

CHAPTERS:

Young LH, Gelfand RA, King JE, Revkin JH, Barrett EJ. An examination of the role of branched chain amino acids in muscle fuel and protein metabolism. in Perspectives in Clinical Nutrition, ed. JM Kinney and P. Borum, Urban and Schwarzenburg, Baltimore-Munich, p261-273, 1989

Revkin JH, Lester D. Vascular imaging and the clinical development of new pharmaceuticals, in Carotid Disease: The Role of Imaging in Diagnosis and Management (eds. Gillard J, Graves M, Hatsukami T, and Yuan C) Cambridge University Press. 2006